Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 24, 2022

And the fact that the legislation is originating from leadership who is intimately familiar with drug policy reform is a firm indicator that this is a serious endeavor. Full story at. New Jersey Senate President Files Psilocybin Legalization Bill That Includes Home Grow Option, Unlike Current Marijuana Law.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

APRIL 21, 2022

MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. Johnson & Roland R. TIMES (Nov.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

JANUARY 19, 2022

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JUNE 19, 2022

The new center is designed to formalize a network of experts across the university based in a range of academic departments as well as existing centers focused on drug policy and substance misuse prevention and recovery. Davis and Slot predicted that as things stand, these therapies could be federally approved in three to five years. “If

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

CannaTech

SEPTEMBER 23, 2019

The pleas of parents fighting to treat their sick children are impossible to ignore, as evidenced by the impact of Billy Caldwell and Alfie Dingley’s parents in shifting the regulatory framework for UK cannabis policy. This bottleneck has left patients and parents to pursue unregulated avenues to access treatment.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial. Co-author Dr Sue Sisley says that the results are promising.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

JUNE 3, 2022

Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

MARCH 1, 2022

Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Andrew Yang. Amanda Feilding.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Veriheal

JULY 18, 2023

Recognizing that the efficacy of treatment relies not only on the therapeutic substances themselves but also on the skill and knowledge of the individuals administering them, this bill explicitly supports the training of practitioners. This could foster a pool of experts well-versed in applying psychedelic-assisted therapy.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98